CY1109223T1 - Υγρα σκευασματα toy g-csf - Google Patents

Υγρα σκευασματα toy g-csf

Info

Publication number
CY1109223T1
CY1109223T1 CY20091100762T CY091100762T CY1109223T1 CY 1109223 T1 CY1109223 T1 CY 1109223T1 CY 20091100762 T CY20091100762 T CY 20091100762T CY 091100762 T CY091100762 T CY 091100762T CY 1109223 T1 CY1109223 T1 CY 1109223T1
Authority
CY
Cyprus
Prior art keywords
csf
polysorbate
toy
liquid preparations
pharmaceutical adjuvants
Prior art date
Application number
CY20091100762T
Other languages
English (en)
Inventor
Michael Mack
Ulrich Kurt Blaschke
Original Assignee
Bioceuticals Arzneimittel Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38226349&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109223(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioceuticals Arzneimittel Ag filed Critical Bioceuticals Arzneimittel Ag
Publication of CY1109223T1 publication Critical patent/CY1109223T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σταθερά στην αποθήκευση υγρά σκευάσματα του G-CSF και μέθοδο για την παραγωγή τους. Η εφεύρεση αφορά ιδιαιτέρως υγρά σκευάσματα, τα οποία περιέχουν τον G-CSF ως δραστική ουσία, οξικό ως ρυθμιστική ουσία, πολυσορβικό 20 ή πολυσορβικό 80 ως επιφανειοδραστική ουσία και προαιρετικά φαρμακευτικά αποδεκτές βοηθητικές ουσίες, όπου τα σκευάσματα έχουν τιμή pΗ μεταξύ 4,1 και 4,4.
CY20091100762T 2006-03-01 2009-07-17 Υγρα σκευασματα toy g-csf CY1109223T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006009437A DE102006009437A1 (de) 2006-03-01 2006-03-01 G-CSF-Flüssigformulierung
EP07712399A EP1988913B1 (de) 2006-03-01 2007-03-01 G-csf-flüssigformulierung

Publications (1)

Publication Number Publication Date
CY1109223T1 true CY1109223T1 (el) 2014-07-02

Family

ID=38226349

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100762T CY1109223T1 (el) 2006-03-01 2009-07-17 Υγρα σκευασματα toy g-csf

Country Status (14)

Country Link
US (1) US20090247450A1 (el)
EP (2) EP2098243A1 (el)
JP (1) JP2009528327A (el)
AT (1) ATE429243T1 (el)
CA (1) CA2644461A1 (el)
CY (1) CY1109223T1 (el)
DE (4) DE102006009437A1 (el)
DK (1) DK1988913T3 (el)
ES (1) ES2326498T3 (el)
PL (1) PL1988913T3 (el)
PT (1) PT1988913E (el)
RU (1) RU2445115C2 (el)
SI (1) SI1988913T1 (el)
WO (1) WO2007099145A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
EP1608688B1 (en) 2003-03-14 2013-02-27 BioGeneriX AG Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2005206796B2 (en) 2004-01-08 2011-06-16 Ratiopharm Gmbh O-linked glycosylation of peptides
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
PL2586456T3 (pl) 2004-10-29 2016-07-29 Ratiopharm Gmbh Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF)
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US20080280818A1 (en) 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
KR20150064246A (ko) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
JP2010536906A (ja) * 2007-08-27 2010-12-02 バイオジェネリクス アーゲー Ｇ−ｃｓｆの液体製剤
EP2197919B1 (en) * 2007-08-27 2014-04-09 ratiopharm GmbH Liquid formulation of g-csf conjugate
DE102007040932A1 (de) * 2007-08-27 2009-03-05 Biogenerix Ag Flüssigformulierung von G-CSF
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
EP2399572A1 (en) * 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE3537708A1 (de) 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
EP0347041A3 (en) 1988-05-13 1990-11-22 Amgen Inc. Compositions and method for treating or preventing infections in animals
DE3835350A1 (de) 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
FR2669646A1 (fr) 1990-11-23 1992-05-29 Lorraine Laminage Procede de traitement d'un effluent aqueux issu d'un procede d'electrozingage, ainsi que procede et installation en comportant application.
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
GB9300356D0 (en) * 1993-01-09 1993-03-03 Tbs Eng Ltd Apparatus for assembling battery plates
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
KR100389726B1 (ko) * 1998-03-06 2003-06-27 쥬가이 세이야쿠 가부시키가이샤 안정한 과립구 콜로니-자극 인자 함유 제제
DK0988861T3 (da) 1998-08-17 2004-04-19 Pfizer Prod Inc Stabiliserede proteinpræparater
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
DE60129432T2 (de) 2000-05-16 2008-04-17 Bolder Biotechnology, Inc., Louisville Verfahren zur rückfaltung von proteinen mit freien cysteinresten
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
WO2005042024A1 (en) 2003-11-04 2005-05-12 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung

Also Published As

Publication number Publication date
PL1988913T3 (pl) 2009-09-30
ES2326498T3 (es) 2009-10-13
EP1988913B1 (de) 2009-04-22
CA2644461A1 (en) 2007-09-07
DE502007000649D1 (de) 2009-06-04
DE102006009437A1 (de) 2007-09-13
WO2007099145A1 (de) 2007-09-07
DK1988913T3 (da) 2009-08-17
RU2008138646A (ru) 2010-04-10
EP2098243A1 (de) 2009-09-09
RU2445115C2 (ru) 2012-03-20
DE202007018618U1 (de) 2008-12-11
PT1988913E (pt) 2009-07-16
US20090247450A1 (en) 2009-10-01
EP1988913A1 (de) 2008-11-12
ATE429243T1 (de) 2009-05-15
JP2009528327A (ja) 2009-08-06
DE202006020194U1 (de) 2007-12-06
SI1988913T1 (sl) 2009-10-31

Similar Documents

Publication Publication Date Title
CY1109223T1 (el) Υγρα σκευασματα toy g-csf
TW200716202A (en) Pediatric formulation of topiramate
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
WO2006086108A3 (en) Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors
ATE464057T1 (de) Gepufferte dialyselösung
BRPI0515520A (pt) composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
WO2006040112A3 (en) Taste-masking pharmaceutical compositions
AR058586A1 (es) Compuesto de 2-carboxitiofeno, formulacion farmaceutica que lo comprende, su uso para la preparacion de un medicamento y combinacion de dicho compuesto con otro agente terapeuticamente activo
WO2009033784A3 (en) Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection
WO2009033785A3 (en) Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
MXPA03011480A (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral.
GEP20043285B (en) Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
WO2009043480A3 (en) Use of leptin (22-56 ) as a therapeutic agent
DK1377164T3 (da) Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo
ATE367165T1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen
SI1970372T1 (sl) Soli 9-oksoakridin-10-ocetne kisline z 1-alkilamino-1-deoksi-polioli
WO2006088945A3 (en) Granulysin peptides and methods of use thereof
WO2003057153A3 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
EP1609473A8 (en) Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
WO2007062334A8 (en) New pleuromutilin derivative and its use
WO2002009717A1 (fr) Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif